United Therapeutics (UTHR) Tops Q1 EPS by 80c, Revenues Beat

United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $3.58, $0.80 better than the analyst estimate of $2.78. Revenue for the quarter came in at $362.6 million versus the consensus estimate of $335.43 million.

"I'm very pleased to report that last quarter we helped more pulmonary arterial hypertension (PAH) patients with our Remodulin, Tyvaso and Orenitram medicines than ever before," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "While we did also experience the disappointment of being unable to prove a morbidity/mortality benefit of esuberaprost in our BEAT phase III trial, it is of course the nature of science that hypotheses are disproven as well as proven. No string of successes is without its setbacks, and we are confident of positive results being proven amongst our many other pivotal studies including the DISTINCT study of dinutuximab for small cell lung cancer, the INCREASE study of Tyvaso in pulmonary hypertension (PH) associated with interstitial lung disease, the PERFECT study of Tyvaso in PH associated with COPD, the SOUTHPAW study of Orenitram in PH associated with heart failure, the ADVANCE OUTCOMES study of ralinepag in PAH, the SAPPHIRE study of autologous gene therapy in PAH and our lung transplantation study."

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

You May Also Be Interested In

• Philip Morris (PM) beats Q1 earnings, revenue estimates; issues upbeat guidance
• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Addus HomeCare (ADUS) Comments on Final Department of Health and Human Services Rule